The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of first subsequent taxane (FST) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who previously received docetaxel intensification (DI) for metastatic castration-sensitive prostate cancer (mCSPC).
 
Gabrielle Robin
Employment - Janssen (I)
 
Naveen S. Basappa
Stock and Other Ownership Interests - illumiSonics
Honoraria - Astellas Pharma; Eisai; Ipsen; Janssen; Merck; Pfizer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Ipsen; Janssen; Merck; Pfizer; Roche Canada
Travel, Accommodations, Expenses - Eisai; Janssen
 
Scott A. North
Honoraria - Astellas Pharma; BMS; Janssen-Ortho; Merck; Pfizer; Roche Canada; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Janssen; Merck; Pfizer; Roche Canada; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Janssen (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca
 
Sunita Ghosh
No Relationships to Disclose
 
Michael Paul Kolinsky
Honoraria - Bayer; Janssen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Ipsen; Janssen; Merck
Research Funding - Janssen (Inst)